NAT2 and CYP1A2 phenotyping with caffeine: Head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios

British Journal of Clinical Pharmacology

Volumn 55, Issue 1, 2003, Pages 62-67

  Nyeki A ^a,c   Buclin, T ^b   Biollaz, J ^b   Decosterd, Laurent Arthur ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

AAMU; AFMU; Caffeine; CYP1A2; NAT2; Phenotyping

Indexed keywords

1 METHYLURIC ACID; 1 METHYLXANTHINE; 1,7 DIMETHYLURIC ACID; 5 ACETAMIDO 6 AMINO 3 METHYLURACIL; 5 ACETAMIDO 6 FORMYLAMINO 3 METHYLURACIL; ACYLTRANSFERASE; CAFFEINE; CYTOCHROME P450 1A2; DRUG METABOLITE; UNCLASSIFIED DRUG; URACIL DERIVATIVE;

ACIDIFICATION; ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYDROLYSIS; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; URINE; URINE PH;

ADULT; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; CYTOCHROME P-450 CYP1A2; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; URACIL;

EID: 0037244653     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01730.x     Document Type: Article

References (25)

1. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 1991;4: 391-407.
2. Smith CAD, Smith G, Wolf CR. Genetic polymorphism in xenobiotic metabolism. Eur J Cancer 1994; 30A: 1921-1935.
3. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984;17: 459-464.
4. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992;52: 643-658.
5. Tucker GT, Rostami-Hodjegan A, Jackson PR. Determination of drug-metabolizing enzyme activityin vivo: pharmacokinetic and statistical issues. Xenobiotica 1998;28: 1255-1273.
6. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996;6: 121-149.
7. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987;42: 157-165.
8. Notarianni LJ, Oliver SE, Dobrocky P, Bennett PN, Silverman BW. Caffeine as a metabolic probe: a comparison of the metabolite ratios used to assess CYP1A2. Br J Clin Pharmacol 1995;39: 65-69.
9. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993;53: 503-514.
10. Andersson T, Holmberg J, Röhss K, Walan A. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 1998;45: 369-375.
11. Kashuba ADM, Bertino JS, Kearns GL et al. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther 1998;63: 540-551.
12. Sinués B, Sáenz MA, Lanuza J et al. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenecity and urine flow. Cancer Epidemiol Biomarkers Prev 1999;8: 159-166.
13. Larsen JT, Hansen LL, Brosen K. Tacrine is not an ideal probe drug for measuring CYP1A2 activityin vivo. Br J Clin Pharmacol 1999;48: 663-668.
14. Bechtel YC, Lelouet H, Hrusovsky S et al. Caffeine metabolism before and after liver transplantation. Int J Clin Pharmacol Ther 2001;39: 53-60.
15. Lorenzo B, Reidenberg MM. Potential artefacts in the use of caffeine to determine acetylation phenotype. Br J Clin Pharmacol 1989;28: 207-208.
16. Butler MA, Lang NP, Young JF et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992;2: 116-127.
17. Wong P, Villeneuve G, Tessier V et al. Stability of 5-acetamido-6-formylamino-3-methyluracil in buffers and urine. J Pharm Biomed Anal 2002;28: 693-700.
18. Graf T, Broly F, Hoffmann F, Probst M, Meyer UA, Howald H. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol 1992;43: 399-403.
19. Bendriss EK, Bechtel YC, Paintaud G et al. Acetylation polymorphism expression in patients before and after liver transplantation: influence of host/graft genotypes. Pharmacogenetics 1998;8: 201-209.
20. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Phamacol Ther 1991;49: 648-657.
21. Zhao B, Seow A, Lee EJD, Lee HP. Correlation between acetylation phenotype and genotype in Chinese women. Eur J Clin Pharmacol 2000;56: 689-692.
22. Guo R, Thormann W. Acetylator phenotypingvia analysis of four caffeine metabolites in human urine by micellar electrokinetic capillary chromatography with multiwavelength detection. Electrophoresis 1993;14: 547-553.
23. Rodopoulos N, Norman A. Determination of caffeine and its metabolites in urine by high-performance liquid chromatography and capillary electrophoresis. Scand J Clin Lab Invest 1994;54: 305-315.
24. Nyéki A, Biollaz J, Kesselring UW, Décosterd LA. Extractionless method for the simultaneous high-performance liquid chromatographic determination of urinary caffeine metabolites for N-acetyltransferase 2, cytochrome P450 1A2 and xanthine oxidase activity assessment. J Chromatogr B 2001; 755: 73-84.
25. Fuchs P, Haefeli WE, Ledermann HR, Wenk M. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. Eur J Clin Pharmacol 1999;54: 869-876.